MannKind's inhalable insulin Afrezza eyes paediatric approval by 2026

MannKind Corporation continues to expand its role in chronic disease treatment with a focus on inhalable insulin and new therapies. The company's flagship product, Afrezza, has gained approval for both Type 1 and Type 2 diabetes. Recent moves, including pipeline acquisitions and regulatory filings, are now drawing renewed attention from investors.

The latest developments suggest a shift in momentum for the biopharma firm, despite past challenges in market adoption. Afrezza, an inhalable insulin, was initially approved for adults with Type 1 and Type 2 diabetes. However, its adoption has lagged behind traditional insulin injections. Controversies and regulatory hurdles have slowed progress, though partnerships—such as Cipla's exclusive distribution rights in India—are now helping to widen its reach.

In October 2025, MannKind submitted a supplemental Biologics License Application (sBLA) to the FDA, seeking approval for Afrezza's use in paediatric patients. If successful, this expansion could significantly broaden the drug's market by Q2 2026. Meanwhile, the company has diversified its portfolio, acquiring a rapid-acting furosemide auto-injector to strengthen its pipeline.

Beyond Afrezza, MannKind manufactures Tyvaso DPI for United Therapeutics Corp. This agreement provides steady revenue through manufacturing fees and a 10% share of sales. The combination of de-risked FDA filings, growing partnerships, and multiple revenue streams is reshaping the company's financial outlook.

While biopharma stocks remain volatile, MannKind's strategic focus on innovation and pipeline growth is gradually improving investor confidence. The company's efforts to expand Afrezza's label and distribution channels suggest a more stable path forward. MannKind's recent regulatory filings and partnerships aim to accelerate Afrezza's adoption and revenue growth. The potential paediatric approval in 2026 could further expand its market presence.

With a diversified pipeline and steady income from manufacturing agreements, the company now offers a clearer risk-reward profile for investors. The shift reflects both regulatory progress and a broader strategy to strengthen its position in chronic disease management.